Monday, March 17, 2025 | 09:01 PM ISTहिंदी में पढें

Home / Content / B2B Connect / Pharma / Zydus Cadila receives US FDA approval for anti-inflammatory drug budesonide

Zydus Cadila receives US FDA approval for anti-inflammatory drug budesonide

Budesonide is estimated to have annual sales of $ 285.8 million, according to IMS

Premium

BS B2B Bureau Ahmedabad

Last Updated : May 05 2017 | 1:48 PM IST

The Ahmedabad-based Zydus Cadila has received the final approval from the US Food & Drug Administration (FDA) to market budesonide capsules, 3 mg (enteric coated). The drug is a corticosteroid used for its anti-inflammatory action.

Zydus Cadila will produce the approved drug at the group's formulation manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales of budesonide is $ 285.8 million (IMS MAT March 2017).

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in